Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2018

01-08-2018 | Original Article

Serum antibody response to Chlamydia trachomatis TroA and HtrA in women with tubal factor infertility

Authors: T. Rantsi, P. Joki-Korpela, K. Hokynar, I. Kalliala, H. Öhman, H-M. Surcel, J. Paavonen, A. Tiitinen, M. Puolakkainen

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2018

Login to get access

Abstract

Persistent genital chlamydial infection may lead to tubal factor infertility (TFI). Chlamydia trachomatis TroA and HtrA are proteins expressed during persistent chlamydial infection in vitro. We studied serum IgG antibody response against these proteins by EIA in women with TFI and in subfertile women without tubal pathology. Altogether, 22 of 258 subfertile women (8.5%) had TFI which was unilateral in 17 cases and bilateral in 5 cases. Overall, 55 (21.3%) of the 258 women had TroA and 39 (15.1%) had HtrA antibodies. Seropositivity to TroA and HtrA was more common among women with TFI than women with other causes for subfertility (45.5 vs. 19.1%, p = 0.004 for TroA; 36.4 vs. 13.1%, p = 0.004 for HtrA). Mean absorbance values and the prevalence of TroA and HtrA antibodies increased with increasing severity of TFI. On the basis of our results, TroA and HtrA serology has the potential to be further developed to a specific biomarker for C. trachomatis-related TFI.
Literature
Metadata
Title
Serum antibody response to Chlamydia trachomatis TroA and HtrA in women with tubal factor infertility
Authors
T. Rantsi
P. Joki-Korpela
K. Hokynar
I. Kalliala
H. Öhman
H-M. Surcel
J. Paavonen
A. Tiitinen
M. Puolakkainen
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3276-9

Other articles of this Issue 8/2018

European Journal of Clinical Microbiology & Infectious Diseases 8/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.